Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predictive Value of Oncogene Mutations for Anti-EGFR Efficacy in mCRC
NCT06226857Phase 3Recruiting
- Sponsor
- City Clinical Oncology Hospital No. 1
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of cetuximab, panitumumab in metastatic colorectal cancer (mCRC), sponsored by City Clinical Oncology Hospital No. 1. Started Jan 2024; status: recruiting.
02
Drugs
cetuximabpanitumumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06226857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06226857.